• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Dipeptiven
    / Cure Medical & Technical Supply

    Active Ingredient *
    L-Glutamine 13.46 g / 100 ml
    L-Alanine 8.2 g / 100 ml

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    10 x 50 ml

    not in the basket chart


    10 X 100 ml

    not in the basket chart


    Adults: Dosage depends on the severity of the catabolic state and on amino acid requirement. A maximum daily dosage of 2 g amino acids/kg body weight should not be exceeded in parenteral nutrition. The supply of alanine and glutamine via Dipeptiven should be taken into consideration in the calculation; the proportion of the amino acid s supplied through Dipeptiven should not exceed approx. 20% of the total supply.
    Daily dose: 1.5 – 2.0 ml of Dipeptiven per kg body weight (equivalent to 0.3 – 0.4 g N(2)-L-alanyl-L-glutamine per kg body weight). This equates to 100 to 140 ml Dipeptiven for a patient of 70 kg body weight.Maximum daily dose: 2.0 ml equivalent to 0.4 g N(2)-L-alanyl-L-glutamine of Dipeptiven per kg body weight.
    For central venous infusion after addition to a compatible infusion solution.Solutions of mixtures with an osmolarity above 800 mosmol/l should be infused by the central venous route.


    As part of an intravenous parenteral nutrition regimen as a supplement to amino acid solutions or an amino acid containing infusion regimen. In patients in extreme cases of hypercatabolic stage such as major abdominal surgery, BMT, diffuse injury of GI mucous.


    Dipeptiven should not be administered to patients with severe renal insufficiency (creatinine clearance < 25 ml/minute), severe hepatic insufficiency, severe metabolic acidosis or known hypersensitivity to the active substances or to any of the excipients.

    Special Precautions

    Regularly monitor liver function parameters in patients with compensated hepatic insufficiency. Administration to children is not recommended. Serum electrolytes, serum osmolarity, water balance, acid-base status as well as liver function tests (alkaline phospatase, ALT, AST), possible symptoms of hyperammonemia should be controlled. The enzymes alkaline phosphatase, GPT, GOT, bilirubin level and the acid-base status should be monitored. The choice of a peripheral or central vein depends on the final osmolarity of the mixture. The general accepted limit for peripheral infusion is about 800 mosmol/l but it varies considerably with the age and general condition of the patient and the characteristics of the peripheral veins. Experience with the use of Dipeptiven for longer periods than nine days is limited.

    Side Effects

    None known when correctly administered.

    Drug interactions

    No interactions are known.

    Pregnancy and Lactation

    Due to lack of experience, Dipeptiven should not be administered during pregnancy and lactation.


    As with other infusion solutions, chills, nausea and vomiting can occur, when the infusion rate of Dipeptiven is exceeded.Infusion shall be stopped immediately in this case.

    Fresenius Kabi